NMS-P383

NMS-P383 is a potent and selective small molecule inhibitor of BRAF kinase, specifically targeting the BRAF V600E mutation. Developed by Nerviano Medical Sciences, it belongs to a class of arylpyrazole derivatives. The compound demonstrates high affinity for the active conformation of the BRAF enzyme and exhibits significant selectivity over a broad panel of other kinases. In preclinical studies, NMS-P383 has shown the ability to inhibit the MAPK signal transduction pathway and suppress the proliferation of cancer cell lines harboring the BRAF V600E mutation. In vivo, oral administration of NMS-P383 resulted in potent tumor growth inhibition in melanoma xenograft models without overt toxicity.